Fig. 4

The protein expression levels of Rufy3 and the state of neuronal axon under LV-shRNA and LV-Rufy3 treatments after vivo and vitro SAH. a Representative bands of Rufy3 detected by western blot under 8p-CPT, LV-shRNA and LV-Rufy3 treatments following vivo SAH. b Representative bands of Rufy3 detected by western blot under LV-shRNA and LV-Rufy3 treatments following vitro SAH. c, d Quantitative analysis of Rufy3 in different groups following vivo and vitro SAH. The sham and control group were used as a control. e Double immunofluorescence analysis of Rufy3 (green, Alexa Fluor 488) and β-tubulin III (NeuN; red, Alexa Fluor 555); nuclei were stained with DAPI (blue). Scale bars = 32 μm. f, g Quantitative fluorescent intensity analysis of Rufy3 and β-tubulin III expressions in different groups. The sham group was used as the standard. h Quantitative analysis of the length of neuronal axon in different groups. i Double immunofluorescence of Rufy3 (green, Alexa Fluor 488) and β-tubulin III (axon; red, Alexa Fluor 555). Nuclei were stained with DAPI (blue). Scale bars = 100 μm. Data are shown as mean ± SEM (n = 6). **P < 0.01, **P < 0.001 vs. Sham group; *P < 0.001 vs. Control group; ^#P < 0.05, ^##P < 0.01 vs. LV-NC1 groups; ^&P < 0.05, ^&&P < 0.01, ^&&&P < 0.001 vs. LV-NC2 group; ^$P < 0.05 vs. LV-Rufy3 group